1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med1998; 338: 853–60.
2. DeBouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses1992; 8: 153–64.
3. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Bethesda, MD, USA: U.S. Department of Health and Human Services, 7 April 2005.
4. Kumar GN, Jayanti V, Lee RD et al. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos1999; 27: 86–91.
5. Marsh K, McDonald E, Sham H et al. Enhancement of ABT-378 pharmacokinetics when administered in combination with ritonavir. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1997. Abstract 210, p. 103. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.